Literature DB >> 34339029

Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Maureen L Drakes1, Patrick J Stiff2.   

Abstract

Ovarian cancer generally escapes diagnosis until the advanced stages. High-grade serous ovarian cancer (HGSOC) is the most frequently occurring form of this malaise and is a disease which has the highest mortality rate of gynecologic cancers. Over recent years it has been revealed that the course of such cancers can be significantly influenced by the nature of immune cells in tumors at the time of diagnosis and by immune cells induced by therapy. Numerous investigators have since focused on disease biology to identify biomarkers or therapeutic targets. Yet, while over the past decade there have been significant improvements in state-of-the-art surgery for ovarian cancer as frontline therapy, there have been limited advancements in the development of novel curative or management drugs for this disease. This chapter discusses the major elements of immune suppression in HGSOC from a biological viewpoint, mechanisms of overcoming resistance to therapies, and recent therapy aimed at improving patient care and survival.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Dendritic cell vaccine therapy; Epigenetic modulation; Immune checkpoint junctions; Immune suppression; Novel therapies; Ovarian cancer; Tumor microenvironment; Tumor-associated macrophages

Year:  2021        PMID: 34339029     DOI: 10.1007/978-3-030-73359-9_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  161 in total

1.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

Review 3.  Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Authors:  Christopher J Lord; Andrew N J Tutt; Alan Ashworth
Journal:  Annu Rev Med       Date:  2014-10-17       Impact factor: 13.739

Review 4.  Regulatory T cells in cancer immunotherapy.

Authors:  Atsushi Tanaka; Shimon Sakaguchi
Journal:  Cell Res       Date:  2016-12-20       Impact factor: 25.617

Review 5.  Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?

Authors:  A Hamaï; H Benlalam; F Meslin; M Hasmim; T Carré; I Akalay; B Janji; G Berchem; M Z Noman; S Chouaib
Journal:  Tissue Antigens       Date:  2010-01

Review 6.  CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.

Authors:  Rong-Fu Wang
Journal:  Hum Immunol       Date:  2008-09-24       Impact factor: 2.850

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 8.  Transcriptional control of effector and memory CD8+ T cell differentiation.

Authors:  Susan M Kaech; Weiguo Cui
Journal:  Nat Rev Immunol       Date:  2012-10-19       Impact factor: 53.106

9.  LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.

Authors:  Ruea-Yea Huang; Cheryl Eppolito; Shashikant Lele; Protul Shrikant; Junko Matsuzaki; Kunle Odunsi
Journal:  Oncotarget       Date:  2015-09-29

10.  Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.

Authors:  Alexander J Cole; Trisha Dwight; Anthony J Gill; Kristie-Ann Dickson; Ying Zhu; Adele Clarkson; Gregory B Gard; Jayne Maidens; Susan Valmadre; Roderick Clifton-Bligh; Deborah J Marsh
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

View more
  1 in total

Review 1.  A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

Authors:  Xiaolin Qing; Liting Liu; Xiguang Mao
Journal:  Comput Math Methods Med       Date:  2022-05-25       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.